Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial

Vaccine

Volumn 29, Issue 35, 2011, Pages 6059-6067

  Aide, Pedro ^a,b   Dobaño, Carlota ^a,c   Sacarlal, Jahit ^a,d   Aponte, John J ^a,c   Mandomando, Inácio ^a,b   Guinovart, Caterina ^a,c   Bassat, Quique ^a,c   Renom, Montse ^a,c   Puyol, Laura ^c   Macete, Eusebio ^a,b   Herreros, Esperanza ^g   Leach, Amanda ^e   Dubois, Marie Claude ^e   Demoitie, Marie Ange ^e   Lievens, Marc ^e   Vekemans, Johan ^e   Loucq, Christian ^f   Ballou, W Ripley ^e   Cohen, Joe ^e   Alonso, Pedro L ^a,c  

^a Ministérioda Saúde   (Mozambique)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^c HOSPITAL CLÍNIC   (Spain)

^d EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f PATH Malaria Vaccine Initiative   (United States)

^g GLAXOSMITHKLINE   (Spain)

Author keywords

Children; Immunogenicity; Malaria; RTS; S AS02 A; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MALARIA VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; MALARIA FALCIPARUM; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL;

ANTIBODIES, PROTOZOAN; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MOZAMBIQUE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TREATMENT OUTCOME;

EID: 79960710582     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.041     Document Type: Article

References (27)

1. WHO World Malaria Report 2009, 2009 [cited 2010 12 July]; Available from: http://whqlibdoc.who.int/publications/2009/9789241563901_eng.pdf.
2. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995, 171(January (6)):1576-1585.
3. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997, 336(January (2)):86-91.
4. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358(December (9297)):1927-1934.
5. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366(December (9502)):2012-2018.
6. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364(October (9443)):1411-1420.
7. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 370(November (9598)):1543-1551.
8. Abdulla S., Oberholzer R., Juma O., Kubhoja S., Machera F., Membi C., et al. Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. N Engl J Med 2008, (December).
9. Barbosa A., Naniche D., Aponte J.J., Manaca M.N., Mandomando I., Aide P., et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun 2009, 77(October (10)):4502-4509.
10. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, (December).
11. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(August (3)):337-346.
12. Waters J.A., Pignatelli M., Brown D., O'Rourke S., Lever A., Thomas H.C. The immune response to hepatitis B virus. Postgrad Med J 1987, 63(Suppl. (2)):51-56.
13. Sacarlal J., Aide P., Aponte J.J., Renom M., Leach A., Mandomando I., et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009, 200(August (3)):329-336.
14. Alonso PL, Saúte, F., Aponte, J.J., Gómez-Olivé, F.X., Nhacolo, A., Thompson, R., Macete, E., Abacassamo, F., Ventura, P.J., Bosch, X., Menéndez, C., Dgedge, M. (2002) Manhiça DSS, Mozambique. In population and health in developing countries. 1st ed. Ottawa: International Development Research Centre (IDRC).
15. Aranda C., Aponte J.J., Saute F., Casimiro S., Pinto J., Sousa C., et al. Entomological characteristics of malaria transmission in Manhica, a rural area in southern Mozambique. J Med Entomol 2005, 42(March (2)):180-186.
16. Nhacolo A.Q., Nhalungo D.A., Sacoor C.N., Aponte J.J., Thompson R., Alonso P. Levels and trends of demographic indices in southern rural Mozambique: evidence from demographic surveillance in Manhica district. BMC Public Health 2006, 6:291.
17. Sacarlal J., Aponte J.J., Aide P., Mandomando I., Bassat Q., Guinovart C., et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 2008, 26(January (2)):174-184.
18. Macete E., Aponte J.J., Guinovart C., Sacarlal J., Ofori-Anyinam O., Mandomando I., et al. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 2007, 12(January (1)):37-46.
19. Cambron P., Jacquet J.M., Hoet B., Lievens M. Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine. Clin Vaccine Immunol 2009, 16(August (8)):1236-1246.
20. Reed G.F., Meade B.D., Steinhoff M.C. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 1995, 96(September (3)):600-603.
21. Lell B., Agnandji S., von Glasenapp I., Haertle S., Oyakhiromen S., Issifou S., et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One 2009, 4(10):e7611.
22. Owusu-Agyei S., Ansong D., Asante K., Kwarteng Owusu S., Owusu R., Wireko Brobby N.A., et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One 2009, 4(10):e7302.
23. Bojang K., Milligan P., Pinder M., Doherty T., Leach A., Ofori-Anyinam O., et al. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin 2009, 5(April (4)):242-247.
24. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006, 211(June):320-337.
25. Wipasa J., Suphavilai C., Okell L.C., Cook J., Corran P.H., Thaikla K., et al. Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 2010, 6(2):e1000770.
26. Guinovart C., Aponte J.J., Sacarlal J., Aide P., Leach A., Bassat Q., et al. Insights into long-lasting protection induced by RTS S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One 2009, 4(4):e5165.
27. Schwenk R., Asher L.V., Chalom I., Lanar D., Sun P., White K., et al. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol 2003, 25(January (1)):17-25.